Hepion Pharmaceuticals Urges Shareholders to Vote 'FOR' All Proposals Ahead of its Upcoming Annual Meeting
globenewswire.com
science
2022-05-31 20:30:00

EDISON, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ('AI')-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ('NASH') and hepatocellular carcinoma ('HCC'), today urged its stockholders to vote 'FOR' all proposals put forth in the definitive proxy statement prior to its June 24, 2022 Annual Meeting of Stockholders. 'As one equity analyst recently observed in a research note, our industry is facing one of the worst biotech tapes in a generation,' said Dr.
